nodes	percent_of_prediction	percent_of_DWPC	metapath
Probenecid—ABCC6—Dactinomycin—skin cancer	0.155	0.177	CbGbCtD
Probenecid—ABCC5—Fluorouracil—skin cancer	0.0801	0.0914	CbGbCtD
Probenecid—ABCC1—Vemurafenib—skin cancer	0.0688	0.0785	CbGbCtD
Probenecid—ABCC3—Fluorouracil—skin cancer	0.0503	0.0575	CbGbCtD
Probenecid—ABCC1—Dactinomycin—skin cancer	0.0457	0.0522	CbGbCtD
Probenecid—SLC22A5—Dactinomycin—skin cancer	0.0435	0.0496	CbGbCtD
Probenecid—ALB—Vismodegib—skin cancer	0.0401	0.0458	CbGbCtD
Probenecid—SLC22A7—Fluorouracil—skin cancer	0.0394	0.0449	CbGbCtD
Probenecid—ABCC4—Fluorouracil—skin cancer	0.0385	0.0439	CbGbCtD
Probenecid—ALB—Vemurafenib—skin cancer	0.0317	0.0362	CbGbCtD
Probenecid—CYP2C8—Vismodegib—skin cancer	0.031	0.0354	CbGbCtD
Probenecid—SLC22A7—Docetaxel—skin cancer	0.0301	0.0343	CbGbCtD
Probenecid—CYP2C19—Vismodegib—skin cancer	0.026	0.0297	CbGbCtD
Probenecid—ABCC1—Docetaxel—skin cancer	0.0236	0.0269	CbGbCtD
Probenecid—CYP2C9—Vismodegib—skin cancer	0.0216	0.0247	CbGbCtD
Probenecid—ABCB1—Vismodegib—skin cancer	0.021	0.024	CbGbCtD
Probenecid—CYP3A4—Temozolomide—skin cancer	0.0181	0.0207	CbGbCtD
Probenecid—CYP3A4—Imiquimod—skin cancer	0.0181	0.0207	CbGbCtD
Probenecid—ABCC2—Docetaxel—skin cancer	0.0175	0.0199	CbGbCtD
Probenecid—ALB—Fluorouracil—skin cancer	0.0143	0.0163	CbGbCtD
Probenecid—CYP3A4—Vismodegib—skin cancer	0.0126	0.0144	CbGbCtD
Probenecid—ABCB1—Dactinomycin—skin cancer	0.011	0.0126	CbGbCtD
Probenecid—CYP2C8—Fluorouracil—skin cancer	0.011	0.0126	CbGbCtD
Probenecid—CYP3A4—Vemurafenib—skin cancer	0.00994	0.0114	CbGbCtD
Probenecid—ABCC6—dermis—skin cancer	0.00911	0.175	CbGeAlD
Probenecid—CYP2C9—Fluorouracil—skin cancer	0.00768	0.00877	CbGbCtD
Probenecid—ABCB1—Docetaxel—skin cancer	0.0057	0.0065	CbGbCtD
Probenecid—SLC2A9—hair follicle—skin cancer	0.0045	0.0863	CbGeAlD
Probenecid—CYP3A4—Docetaxel—skin cancer	0.00341	0.0039	CbGbCtD
Probenecid—Procaine—SCN10A—skin cancer	0.00293	0.659	CrCbGaD
Probenecid—PANX1—connective tissue—skin cancer	0.00239	0.0458	CbGeAlD
Probenecid—SLC2A9—connective tissue—skin cancer	0.00216	0.0415	CbGeAlD
Probenecid—PANX1—mammalian vulva—skin cancer	0.00197	0.0377	CbGeAlD
Probenecid—ABCC5—hair follicle—skin cancer	0.00186	0.0356	CbGeAlD
Probenecid—SLC16A7—nipple—skin cancer	0.0018	0.0345	CbGeAlD
Probenecid—Alopecia—Vismodegib—skin cancer	0.00174	0.0258	CcSEcCtD
Probenecid—ABCC11—female reproductive system—skin cancer	0.00161	0.031	CbGeAlD
Probenecid—Toxic epidermal necrolysis—Vemurafenib—skin cancer	0.00159	0.0235	CcSEcCtD
Probenecid—SLC2A9—female reproductive system—skin cancer	0.00153	0.0293	CbGeAlD
Probenecid—Procainamide—SCN10A—skin cancer	0.00151	0.341	CrCbGaD
Probenecid—PANX1—head—skin cancer	0.00141	0.027	CbGeAlD
Probenecid—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.00135	0.0199	CcSEcCtD
Probenecid—ABCC6—connective tissue—skin cancer	0.00131	0.0252	CbGeAlD
Probenecid—Aplastic anaemia—Dactinomycin—skin cancer	0.00129	0.0191	CcSEcCtD
Probenecid—Decreased appetite—Vismodegib—skin cancer	0.00122	0.0181	CcSEcCtD
Probenecid—Pain—Vismodegib—skin cancer	0.0012	0.0178	CcSEcCtD
Probenecid—Aplastic anaemia—Temozolomide—skin cancer	0.00117	0.0173	CcSEcCtD
Probenecid—Erythema multiforme—Vemurafenib—skin cancer	0.00115	0.0171	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.00115	0.017	CcSEcCtD
Probenecid—ABCC1—hair follicle—skin cancer	0.0011	0.0211	CbGeAlD
Probenecid—Alopecia—Vemurafenib—skin cancer	0.00108	0.016	CcSEcCtD
Probenecid—SLC16A7—mammalian vulva—skin cancer	0.00105	0.0202	CbGeAlD
Probenecid—Pruritus—Vismodegib—skin cancer	0.000992	0.0147	CcSEcCtD
Probenecid—PANX1—lymph node—skin cancer	0.000985	0.0189	CbGeAlD
Probenecid—Erythema multiforme—Imiquimod—skin cancer	0.000983	0.0146	CcSEcCtD
Probenecid—Flushing—Imiquimod—skin cancer	0.000965	0.0143	CcSEcCtD
Probenecid—Alopecia—Imiquimod—skin cancer	0.000919	0.0136	CcSEcCtD
Probenecid—SLC16A7—female reproductive system—skin cancer	0.000901	0.0173	CbGeAlD
Probenecid—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.000897	0.0133	CcSEcCtD
Probenecid—SLC2A9—lymph node—skin cancer	0.000893	0.0171	CbGeAlD
Probenecid—Vomiting—Vismodegib—skin cancer	0.000892	0.0132	CcSEcCtD
Probenecid—Dermatitis—Vismodegib—skin cancer	0.000883	0.0131	CcSEcCtD
Probenecid—Anaphylactic shock—Vemurafenib—skin cancer	0.000866	0.0128	CcSEcCtD
Probenecid—SLC10A1—female reproductive system—skin cancer	0.000841	0.0161	CbGeAlD
Probenecid—Nausea—Vismodegib—skin cancer	0.000833	0.0123	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.000811	0.012	CcSEcCtD
Probenecid—Haematuria—Bleomycin—skin cancer	0.000785	0.0116	CcSEcCtD
Probenecid—ABCC6—head—skin cancer	0.000774	0.0149	CbGeAlD
Probenecid—SLC16A1—epithelium—skin cancer	0.000772	0.0148	CbGeAlD
Probenecid—SLC22A11—female reproductive system—skin cancer	0.000768	0.0147	CbGeAlD
Probenecid—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.000761	0.0113	CcSEcCtD
Probenecid—Decreased appetite—Vemurafenib—skin cancer	0.000753	0.0112	CcSEcCtD
Probenecid—SLC16A7—head—skin cancer	0.000752	0.0144	CbGeAlD
Probenecid—ABCC1—nipple—skin cancer	0.000745	0.0143	CbGeAlD
Probenecid—Pollakiuria—Temozolomide—skin cancer	0.000719	0.0107	CcSEcCtD
Probenecid—Anorexia—Imiquimod—skin cancer	0.000704	0.0104	CcSEcCtD
Probenecid—SLC10A1—head—skin cancer	0.000703	0.0135	CbGeAlD
Probenecid—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000688	0.0102	CcSEcCtD
Probenecid—Flushing—Bleomycin—skin cancer	0.000686	0.0102	CcSEcCtD
Probenecid—Body temperature increased—Vemurafenib—skin cancer	0.000685	0.0101	CcSEcCtD
Probenecid—SLCO1C1—head—skin cancer	0.000661	0.0127	CbGeAlD
Probenecid—SLC22A5—nipple—skin cancer	0.000655	0.0126	CbGeAlD
Probenecid—Alopecia—Bleomycin—skin cancer	0.000653	0.00967	CcSEcCtD
Probenecid—Erythema multiforme—Dactinomycin—skin cancer	0.000651	0.00965	CcSEcCtD
Probenecid—Decreased appetite—Imiquimod—skin cancer	0.000642	0.00951	CcSEcCtD
Probenecid—Flushing—Dactinomycin—skin cancer	0.000639	0.00947	CcSEcCtD
Probenecid—Hypersensitivity—Vemurafenib—skin cancer	0.000638	0.00946	CcSEcCtD
Probenecid—Pain—Imiquimod—skin cancer	0.000632	0.00936	CcSEcCtD
Probenecid—Pruritus—Vemurafenib—skin cancer	0.000613	0.00908	CcSEcCtD
Probenecid—Alopecia—Dactinomycin—skin cancer	0.000609	0.00902	CcSEcCtD
Probenecid—Anaemia—Bleomycin—skin cancer	0.000594	0.00881	CcSEcCtD
Probenecid—Erythema multiforme—Temozolomide—skin cancer	0.000589	0.00873	CcSEcCtD
Probenecid—Urticaria—Imiquimod—skin cancer	0.000587	0.00869	CcSEcCtD
Probenecid—Body temperature increased—Imiquimod—skin cancer	0.000584	0.00865	CcSEcCtD
Probenecid—Flushing—Temozolomide—skin cancer	0.000578	0.00857	CcSEcCtD
Probenecid—Leukopenia—Bleomycin—skin cancer	0.000576	0.00853	CcSEcCtD
Probenecid—SLC16A1—female reproductive system—skin cancer	0.000573	0.011	CbGeAlD
Probenecid—Dizziness—Vemurafenib—skin cancer	0.000573	0.00849	CcSEcCtD
Probenecid—Anaemia—Dactinomycin—skin cancer	0.000554	0.00821	CcSEcCtD
Probenecid—Vomiting—Vemurafenib—skin cancer	0.000551	0.00816	CcSEcCtD
Probenecid—Alopecia—Temozolomide—skin cancer	0.000551	0.00816	CcSEcCtD
Probenecid—Dermatitis—Vemurafenib—skin cancer	0.000546	0.00808	CcSEcCtD
Probenecid—Hypersensitivity—Imiquimod—skin cancer	0.000544	0.00806	CcSEcCtD
Probenecid—Headache—Vemurafenib—skin cancer	0.000543	0.00804	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000539	0.00799	CcSEcCtD
Probenecid—Leukopenia—Dactinomycin—skin cancer	0.000537	0.00795	CcSEcCtD
Probenecid—ABCC3—female reproductive system—skin cancer	0.000529	0.0101	CbGeAlD
Probenecid—SLC16A7—lymph node—skin cancer	0.000527	0.0101	CbGeAlD
Probenecid—Anaphylactic shock—Bleomycin—skin cancer	0.000525	0.00778	CcSEcCtD
Probenecid—Pruritus—Imiquimod—skin cancer	0.000523	0.00774	CcSEcCtD
Probenecid—Nausea—Vemurafenib—skin cancer	0.000515	0.00762	CcSEcCtD
Probenecid—Alopecia—Fluorouracil—skin cancer	0.000507	0.00752	CcSEcCtD
Probenecid—Anaemia—Temozolomide—skin cancer	0.000501	0.00743	CcSEcCtD
Probenecid—Anorexia—Bleomycin—skin cancer	0.0005	0.00741	CcSEcCtD
Probenecid—Dizziness—Imiquimod—skin cancer	0.000489	0.00724	CcSEcCtD
Probenecid—Leukopenia—Temozolomide—skin cancer	0.000486	0.00719	CcSEcCtD
Probenecid—SLC16A1—head—skin cancer	0.000479	0.00919	CbGeAlD
Probenecid—Vomiting—Imiquimod—skin cancer	0.00047	0.00696	CcSEcCtD
Probenecid—Anorexia—Dactinomycin—skin cancer	0.000467	0.00691	CcSEcCtD
Probenecid—Dermatitis—Imiquimod—skin cancer	0.000465	0.00689	CcSEcCtD
Probenecid—Headache—Imiquimod—skin cancer	0.000463	0.00686	CcSEcCtD
Probenecid—SLCO1C1—lymph node—skin cancer	0.000463	0.00887	CbGeAlD
Probenecid—Anaemia—Fluorouracil—skin cancer	0.000462	0.00684	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000458	0.00678	CcSEcCtD
Probenecid—Decreased appetite—Bleomycin—skin cancer	0.000456	0.00676	CcSEcCtD
Probenecid—Pain—Bleomycin—skin cancer	0.000449	0.00665	CcSEcCtD
Probenecid—Leukopenia—Fluorouracil—skin cancer	0.000447	0.00663	CcSEcCtD
Probenecid—Anaphylactic shock—Temozolomide—skin cancer	0.000443	0.00656	CcSEcCtD
Probenecid—ABCC3—head—skin cancer	0.000442	0.00848	CbGeAlD
Probenecid—Nausea—Imiquimod—skin cancer	0.000439	0.0065	CcSEcCtD
Probenecid—ABCC4—female reproductive system—skin cancer	0.000437	0.00838	CbGeAlD
Probenecid—ABCC1—mammalian vulva—skin cancer	0.000435	0.00834	CbGeAlD
Probenecid—Decreased appetite—Dactinomycin—skin cancer	0.000425	0.0063	CcSEcCtD
Probenecid—ABCC2—female reproductive system—skin cancer	0.000423	0.00811	CbGeAlD
Probenecid—Anorexia—Temozolomide—skin cancer	0.000422	0.00625	CcSEcCtD
Probenecid—ABCB1—blood vessel—skin cancer	0.00042	0.00807	CbGeAlD
Probenecid—SLC22A5—skin of body—skin cancer	0.000419	0.00804	CbGeAlD
Probenecid—Pain—Dactinomycin—skin cancer	0.000419	0.0062	CcSEcCtD
Probenecid—Urticaria—Bleomycin—skin cancer	0.000417	0.00618	CcSEcCtD
Probenecid—Body temperature increased—Bleomycin—skin cancer	0.000415	0.00615	CcSEcCtD
Probenecid—Anaphylactic shock—Fluorouracil—skin cancer	0.000408	0.00604	CcSEcCtD
Probenecid—SLC22A1—head—skin cancer	0.000394	0.00755	CbGeAlD
Probenecid—Erythema multiforme—Docetaxel—skin cancer	0.000392	0.0058	CcSEcCtD
Probenecid—Anorexia—Fluorouracil—skin cancer	0.000389	0.00576	CcSEcCtD
Probenecid—Body temperature increased—Dactinomycin—skin cancer	0.000387	0.00573	CcSEcCtD
Probenecid—Hypersensitivity—Bleomycin—skin cancer	0.000387	0.00573	CcSEcCtD
Probenecid—Decreased appetite—Temozolomide—skin cancer	0.000385	0.0057	CcSEcCtD
Probenecid—Flushing—Docetaxel—skin cancer	0.000385	0.0057	CcSEcCtD
Probenecid—SLCO1A2—head—skin cancer	0.000379	0.00727	CbGeAlD
Probenecid—Pain—Temozolomide—skin cancer	0.000379	0.00561	CcSEcCtD
Probenecid—Pruritus—Bleomycin—skin cancer	0.000371	0.0055	CcSEcCtD
Probenecid—ABCC5—lymph node—skin cancer	0.000369	0.00707	CbGeAlD
Probenecid—Alopecia—Docetaxel—skin cancer	0.000366	0.00543	CcSEcCtD
Probenecid—ABCC4—head—skin cancer	0.000365	0.007	CbGeAlD
Probenecid—SLC22A8—head—skin cancer	0.000362	0.00694	CbGeAlD
Probenecid—Hypersensitivity—Dactinomycin—skin cancer	0.000361	0.00534	CcSEcCtD
Probenecid—Decreased appetite—Fluorouracil—skin cancer	0.000355	0.00525	CcSEcCtD
Probenecid—Urticaria—Temozolomide—skin cancer	0.000352	0.00521	CcSEcCtD
Probenecid—Body temperature increased—Temozolomide—skin cancer	0.00035	0.00518	CcSEcCtD
Probenecid—Pain—Fluorouracil—skin cancer	0.000349	0.00517	CcSEcCtD
Probenecid—SLC16A1—lymph node—skin cancer	0.000335	0.00643	CbGeAlD
Probenecid—Vomiting—Bleomycin—skin cancer	0.000334	0.00494	CcSEcCtD
Probenecid—Anaemia—Docetaxel—skin cancer	0.000333	0.00494	CcSEcCtD
Probenecid—Dermatitis—Bleomycin—skin cancer	0.000331	0.0049	CcSEcCtD
Probenecid—SLC22A5—female reproductive system—skin cancer	0.000328	0.00628	CbGeAlD
Probenecid—Hypersensitivity—Temozolomide—skin cancer	0.000326	0.00483	CcSEcCtD
Probenecid—Urticaria—Fluorouracil—skin cancer	0.000324	0.0048	CcSEcCtD
Probenecid—Leukopenia—Docetaxel—skin cancer	0.000323	0.00478	CcSEcCtD
Probenecid—Body temperature increased—Fluorouracil—skin cancer	0.000322	0.00478	CcSEcCtD
Probenecid—CYP2C8—female reproductive system—skin cancer	0.000317	0.00608	CbGeAlD
Probenecid—Pruritus—Temozolomide—skin cancer	0.000313	0.00464	CcSEcCtD
Probenecid—Nausea—Bleomycin—skin cancer	0.000312	0.00462	CcSEcCtD
Probenecid—Vomiting—Dactinomycin—skin cancer	0.000311	0.00461	CcSEcCtD
Probenecid—ABCC3—lymph node—skin cancer	0.00031	0.00594	CbGeAlD
Probenecid—Hypersensitivity—Fluorouracil—skin cancer	0.000301	0.00445	CcSEcCtD
Probenecid—Anaphylactic shock—Docetaxel—skin cancer	0.000294	0.00436	CcSEcCtD
Probenecid—Dizziness—Temozolomide—skin cancer	0.000293	0.00434	CcSEcCtD
Probenecid—Nausea—Dactinomycin—skin cancer	0.000291	0.00431	CcSEcCtD
Probenecid—Pruritus—Fluorouracil—skin cancer	0.000289	0.00428	CcSEcCtD
Probenecid—CYP2C9—female reproductive system—skin cancer	0.000282	0.0054	CbGeAlD
Probenecid—Vomiting—Temozolomide—skin cancer	0.000281	0.00417	CcSEcCtD
Probenecid—Anorexia—Docetaxel—skin cancer	0.000281	0.00416	CcSEcCtD
Probenecid—Dermatitis—Temozolomide—skin cancer	0.000279	0.00413	CcSEcCtD
Probenecid—Headache—Temozolomide—skin cancer	0.000277	0.00411	CcSEcCtD
Probenecid—Dizziness—Fluorouracil—skin cancer	0.00027	0.004	CcSEcCtD
Probenecid—ALB—lymph node—skin cancer	0.000264	0.00506	CbGeAlD
Probenecid—Nausea—Temozolomide—skin cancer	0.000263	0.0039	CcSEcCtD
Probenecid—Vomiting—Fluorouracil—skin cancer	0.000259	0.00384	CcSEcCtD
Probenecid—Dermatitis—Fluorouracil—skin cancer	0.000257	0.00381	CcSEcCtD
Probenecid—Decreased appetite—Docetaxel—skin cancer	0.000256	0.00379	CcSEcCtD
Probenecid—Headache—Fluorouracil—skin cancer	0.000256	0.00379	CcSEcCtD
Probenecid—ABCC4—lymph node—skin cancer	0.000256	0.0049	CbGeAlD
Probenecid—Pain—Docetaxel—skin cancer	0.000252	0.00373	CcSEcCtD
Probenecid—ABCC2—lymph node—skin cancer	0.000247	0.00474	CbGeAlD
Probenecid—Nausea—Fluorouracil—skin cancer	0.000242	0.00359	CcSEcCtD
Probenecid—Body temperature increased—Docetaxel—skin cancer	0.000233	0.00345	CcSEcCtD
Probenecid—ABCC1—lymph node—skin cancer	0.000218	0.00418	CbGeAlD
Probenecid—Hypersensitivity—Docetaxel—skin cancer	0.000217	0.00321	CcSEcCtD
Probenecid—CYP3A4—female reproductive system—skin cancer	0.000215	0.00412	CbGeAlD
Probenecid—Pruritus—Docetaxel—skin cancer	0.000208	0.00309	CcSEcCtD
Probenecid—ABCB1—epithelium—skin cancer	0.000205	0.00393	CbGeAlD
Probenecid—Dizziness—Docetaxel—skin cancer	0.000195	0.00288	CcSEcCtD
Probenecid—SLC22A5—lymph node—skin cancer	0.000192	0.00368	CbGeAlD
Probenecid—Vomiting—Docetaxel—skin cancer	0.000187	0.00277	CcSEcCtD
Probenecid—Dermatitis—Docetaxel—skin cancer	0.000185	0.00275	CcSEcCtD
Probenecid—Headache—Docetaxel—skin cancer	0.000184	0.00273	CcSEcCtD
Probenecid—ABCB1—mammalian vulva—skin cancer	0.000178	0.00341	CbGeAlD
Probenecid—Nausea—Docetaxel—skin cancer	0.000175	0.00259	CcSEcCtD
Probenecid—ABCB1—lymphoid tissue—skin cancer	0.000158	0.00302	CbGeAlD
Probenecid—ABCB1—female reproductive system—skin cancer	0.000152	0.00292	CbGeAlD
Probenecid—ABCB1—head—skin cancer	0.000127	0.00244	CbGeAlD
Probenecid—ABCB1—lymph node—skin cancer	8.89e-05	0.00171	CbGeAlD
